{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:53:57Z","timestamp":1792515237197,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Meta<\/jats:italic>\n                      -[\n                      <jats:sup>1<\/jats:sup>\n                      \u2078F]fluorobenzylguanidine ([\n                      <jats:sup>1<\/jats:sup>\n                      \u2078F]mFBG) PET-CT is a novel imaging modality for norepinephrine transporter-expressing tumours, such as neuroblastoma and phaeochromocytoma, enabling quantitative assessment and improved diagnostic accuracy compared to\n                      <jats:italic>meta<\/jats:italic>\n                      -[\n                      <jats:sup>123<\/jats:sup>\n                      I]iodobenzylguanidine ([\n                      <jats:sup>123<\/jats:sup>\n                      I]mIBG) scintigraphy. This study aims to: 1) Identify the optimal standardised uptake value (SUV) normalisation method: body weight (BW) or lean body mass (LBM); 2) Determine the most stable reference tissue with SUV uptake below pathological levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analysed 63 [\n                      <jats:sup>1<\/jats:sup>\n                      \u2078F]mFBG PET-CTs from 35 patients (20 paediatric neuroblastoma, 15 adult phaeochromocytoma). SUV\n                      <jats:sub>mean<\/jats:sub>\n                      was measured in the liver, blood pool, bone marrow, and muscle, normalised using BW (SUVBW), LBM via James (SUVLBMJames), and LBM via Janmahasatian (SUVLBMJanma). Variability of SUVs and their correlation with weight were assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      LBM-based normalisation reduced SUV variability compared to BW-based normalisation. Bone marrow demonstrated the lowest variability and least weight dependency (r\n                      <jats:sup>2<\/jats:sup>\n                      0.45 for SUVBW versus 0.31 for SUVLBMJanma). The liver had the highest SUVs, increasing the risk of false negatives if used as reference\u00a0tissue, while the blood pool had the lowest SUVs, raising the risk of false positives. Muscle showed relatively stable SUVs with increasing weight\u00a0but higher variability\u00a0than bone marrow.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      LBM-based SUV normalisation reduces weight dependency for [\n                      <jats:sup>1<\/jats:sup>\n                      \u2078F]mFBG PET-CT. Bone marrow is the most reliable reference tissue due to its low variability and balanced SUVs, while muscle may serve as an alternative if diffuse bone marrow uptake is present. These findings support standardising LBM-adjusted SUV methods and using bone marrow as the primary reference tissue to enhance diagnostic accuracy.\n                    <\/jats:p>\n                    <jats:p>\n                      Clinical trial registration:\u00a0\n                      <jats:bold>EudraCT Number<\/jats:bold>\n                      : 2019\u2013003713-33;\u00a0\n                      <jats:bold>EU Clinical Trials Number<\/jats:bold>\n                      : 2024\u2013513622-35\u201300.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07242-x","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T03:36:50Z","timestamp":1743737810000},"page":"3773-3780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["SUV normalisation and reference tissue selection for [1\u2078F]mFBG PET-CT in paediatric and adult patients"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6165-0902","authenticated-orcid":false,"given":"Atia","family":"Samim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6436-0660","authenticated-orcid":false,"given":"Diederik P. D.","family":"Suurd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8546-8283","authenticated-orcid":false,"given":"Rob","family":"van Rooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0503-5838","authenticated-orcid":false,"given":"Max M.","family":"van Noesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-9790","authenticated-orcid":false,"given":"Marnix G. E. H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8824-8697","authenticated-orcid":false,"given":"Arthur J. A. T.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8005-2833","authenticated-orcid":false,"given":"Nelleke","family":"Tolboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1000-3534","authenticated-orcid":false,"given":"Lise","family":"Borgwardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4452-0748","authenticated-orcid":false,"given":"Godelieve A. M.","family":"Tytgat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6270-9483","authenticated-orcid":false,"given":"Bart","family":"de Keizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"7242_CR1","doi-asserted-by":"crossref","unstructured":"Samim A, Tytgat GAM, Bleeker G, Wenker STM, Chatalic KLS, Poot AJ, et al. Nuclear medicine imaging in neuroblastoma: Current status and new developments. J Pers Med. 2021;11.","DOI":"10.3390\/jpm11040270"},{"key":"7242_CR2","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s00259-022-06063-6","volume":"50","author":"A Samim","year":"2023","unstructured":"Samim A, Blom T, Poot AJ, Windhorst AD, Fiocco M, Tolboom N, et al. [(18)F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2023;50:1146\u201357.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7242_CR3","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1007\/s00259-023-06221-4","volume":"50","author":"P Wang","year":"2023","unstructured":"Wang P, Li T, Liu Z, Jin M, Su Y, Zhang J, et al. [18F]MFBG PET\/CT outperforming [123I]MIBG SPECT\/CT in the evaluation of neuroblastoma. Eur J Nucl Med Mol Imaging. 2023;50:3097\u2013106.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7242_CR4","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1007\/s00259-023-06160-0","volume":"50","author":"L Borgwardt","year":"2023","unstructured":"Borgwardt L, Brok JS, Andersen KF, Madsen J, Gillings N, Fosb\u00f8l M\u00d8, et al. [18F]mFBG long axial field of view PET-CT without general anaesthesia reveals concise extension of neuroblastoma in a 9-month-old boy. Eur J Nucl Med Mol Imaging. 2023;50:2563\u20134.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7242_CR5","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.2967\/jnumed.123.267256","volume":"65","author":"L Borgwardt","year":"2024","unstructured":"Borgwardt L, Brok J, Andersen KF, Madsen J, Gillings N, Fosb\u00f8l M\u00d8, et al. Performing [18F]MFBG Long-Axial-Field-of-View PET\/CT Without Sedation or General Anesthesia for Imaging of Children with Neuroblastoma. J Nucl Med. 2024;65:1286\u201392.","journal-title":"J Nucl Med"},{"key":"7242_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s00259-016-3516-0","volume":"44","author":"V Lewington","year":"2017","unstructured":"Lewington V, Lambert B, Poetschger U, Sever ZB, Giammarile F, McEwan AJB, et al. 123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting, method by an international panel. Eur J Nucl Med Mol Imaging. 2017;44:234\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7242_CR7","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1200\/JCO.2003.09.122","volume":"21","author":"KK Matthay","year":"2003","unstructured":"Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM, et al. Correlation of early metastatic response by 123I- metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol. 2003;21:2486\u201391.","journal-title":"J Clin Oncol"},{"key":"7242_CR8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s40336-020-00392-y","volume":"8","author":"H Khalatbari","year":"2020","unstructured":"Khalatbari H, Shulkin BL, Parisi MT. Pictorial review of the clinical applications of MIBG in neuroblastoma: current practices. Clin Transl Imaging. 2020;8:483\u2013507.","journal-title":"Clin Transl Imaging"},{"key":"7242_CR9","doi-asserted-by":"crossref","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP, et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology. 2014;32:3048\u201358.","DOI":"10.1200\/JCO.2013.53.5229"},{"key":"7242_CR10","doi-asserted-by":"crossref","unstructured":"Joo Hyun O, Lodge MA, Wahl RL. Practical percist: A simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280:576\u201384.","DOI":"10.1148\/radiol.2016142043"},{"key":"7242_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1467-3010.1977.tb00966.x","volume":"4","author":"WPT James","year":"1977","unstructured":"James WPT. Research on obesity Nutr Bull. 1977;4:187\u201390.","journal-title":"Research on obesity Nutr Bull"},{"key":"7242_CR12","doi-asserted-by":"crossref","unstructured":"Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44.","DOI":"10.2165\/00003088-200544100-00004"},{"key":"7242_CR13","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2967\/jnumed.113.136986","volume":"55","author":"AK Tahari","year":"2014","unstructured":"Tahari AK, Chien D, Azadi JR, Wahl RL. Optimum lean body formulation for correction of standardized uptake value in PET imaging. J Nucl Med. 2014;55:1481\u20134.","journal-title":"J Nucl Med"},{"key":"7242_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2967\/jnmt.119.233353","volume":"48","author":"I Sarikaya","year":"2020","unstructured":"Sarikaya I, Albatineh AN, Sarikaya A. Revisiting weight-normalized SUV and lean-body-mass-normalized SUV in PET studies. J Nucl Med Technol. 2020;48:163\u20137.","journal-title":"J Nucl Med Technol"},{"key":"7242_CR15","doi-asserted-by":"crossref","unstructured":"Badawe EM, Abdel Gawad H, El-Nagdy MS, Khalil MM. Variations induced by body weight and background lesion normalization in standardized uptake value estimated by F18-FDG PET\/CT. Eur J Hybrid Imaging. 2022;6.","DOI":"10.1186\/s41824-022-00142-5"},{"key":"7242_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/MNM.0000000000000935","volume":"40","author":"G Keramida","year":"2019","unstructured":"Keramida G, Peters AM. The appropriate whole body metric for calculating standardised uptake value and the influence of sex. Nucl Med Commun. 2019;40:3\u20137.","journal-title":"Nucl Med Commun"},{"key":"7242_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1148\/radiology.213.2.r99nv37521","volume":"213","author":"Y Sugawara","year":"1999","unstructured":"Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the Standardized Uptake Value for FDG: Variations with Body Weight and Methods for Correction. Radiology. 1999;213:521\u20135.","journal-title":"Radiology"},{"key":"7242_CR18","doi-asserted-by":"crossref","unstructured":"de Vries ISA, Lodema S, Braat AJAT, Merks JHM, van Rooij R, de Keizer B. Improving accuracy of SUV estimates in paediatric oncology: Recommending against the use of body weight corrected SUV in [18F]FDG PET. Eur J Nucl Med Mol Imaging. 2025;","DOI":"10.1007\/s00259-025-07104-6"},{"key":"7242_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00259-001-0662-8","volume":"29","author":"H Yeung","year":"2002","unstructured":"Yeung H, Sanches A, Squire O, Macapinlac H, Larson S, Erdi Y. Standardized uptake value in pediatric patients: An investigation to determine the optimum measurement parameter. Eur J Nucl Med. 2002;29:61\u20136.","journal-title":"Eur J Nucl Med"},{"issue":"5","key":"7242_CR20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/bja\/aer078","volume":"106","author":"AM Peters","year":"2011","unstructured":"Peters AM, Snelling HLR, Glass DM, Nahmias C, Sikdar T, Webster BH. Estimation of lean body mass in children. Br J Anaesth. 2011;106(5):719\u201323. https:\/\/doi.org\/10.1093\/bja\/aer078.","journal-title":"Br J Anaesth"},{"issue":"1","key":"7242_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40658-019-0257-8","volume":"6","author":"R Boellaard","year":"2019","unstructured":"Boellaard R, Zijlstra J, Hoekstra OS, Oprea-Lager DE. Quantitative implications of the updated EARL 2019 PET\u2013CT performance standards. EJNMMI Phys. 2019;6(1):10. https:\/\/doi.org\/10.1186\/s40658-019-0257-8.","journal-title":"EJNMMI Phys"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07242-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07242-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07242-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:50:16Z","timestamp":1757148616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07242-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7242"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07242-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for the publication of these data was given by the local ethics committee (PMCLAB2021.199). The Medial Research Ethics Committee (MREC) NedMec has confirmed that no ethical approval is required. This study is retrospective and observational. Data was pseudonymized and served the purpose of clinical research. The study was performed in accordance with the principles enunciated in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MGEHL has acted as a consultant for and received research support from Boston Scientific, Terumo, and Quirem Medical; which had no role in the funding, analysis, interpretation, or writing of the manuscript. AJATB has acted as a consultant for Boston Scientific, Terumo, GE Healthcare and Telix Pharmaceuticals, and received research support from Boston Scientific, Terumo, Ariceum Therapeutics and Telix Pharmaceuticals; which had no role in the funding, analysis, interpretation, or writing of the manuscript. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}